J Urol. 1997 Dec;158(6):2069-73.
Enger B1, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A.
We examined the efficacy of potassium-magnesium citrate in prevenng recurrent
calcium oxalate kidney calculi.
MATERIALS AND METHODS:
We conducted a prospective double-blind study of 64 patients who were randomly assigned to receive placebo or potassium-magnesium citrate (42 mEq.
potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years.
New calculi formed in 63.6% of subjects receiving placebo and in 12.9% of subjects receiving potassium-magnesium citrate. When compared with placebo, the relative risk of treatment failure for potassium-magnesium citrate was 0.16 (95% confidence interval 0.05 to 0.46). Potassium-magnesium citrate had a statistically significant effect (relative risk 0.10, 95% confidence interval 0.03 to 0.36) even after adjustment for possible confounders, including age, pretreatment calculous event rate and urinary biochemical abnormalities.
Potassium-magnesium citrate effectively prevents recurrent calcium oxalate stones, and this treatment given for up to 3 years reduces risk of recurrence by 85%.